AD
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth
Latest NAV
+17.50% 1Y
Sign In to Add to Portfolio
Benchmark: BSE Healthcare TRI
Expense ratio
1.02%
AUM
₹1,103 Cr
Min SIP
₹100
Min lump sum
₹1,000
1Y
+17.50%
3Y (ann.)
+20.10%
5Y (ann.)
+13.98%
Launched
Jul 2019
Where the NAV sits & how risky it is
₹39.22
52-week range
at 77%
₹39.22
Low 29 Jan 2026₹32.36
High 31 Aug 2026₹41.23
Risk level
Very High
Low
Very high
NAV history
11 Jul 2019
Since inception
05 Oct 2026
Returns by period
1W
-2.96%
1M
-3.01%
3M
+2.78%
6M
+18.84%
1Y
+17.50%
3Y
+20.10%
5Y
+13.98%
3Y and 5Y returns are annualised.
Return calculator
You invest
—
Est. gain
—
Est. value
—
Invested Gain
Invested
Projected value
min SIP ₹100
Estimate only. It assumes the selected past return repeats every year; 3Y and 5Y figures are taken as annualised. Actual returns vary and are not guaranteed.
Where your money goes
AS OF 31 MAY 2026
Equity 96.83%
Cash & other 3.28%
Sector split
Country split
Top 5 hold 33.6%
Top 10 hold 52.2%
38 equity holdings
Equity holdings
(top 30)
| # | Holding | Sector | Country | Weight | YTD |
|---|---|---|---|---|---|
| 1 | Sun Pharmaceutical
INE044A01036 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
12.42%
|
+4.97% |
| 2 | Apollo Hospitals
INE437A01024 |
Healthcare Medical Care Facilities |
India |
7.31%
|
+20.74% |
| 3 | Torrent Pharmaceuticals
INE685A01028 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
4.75%
|
+19.75% |
| 4 | J B Chemicals and Pharmaceuticals
INE572A01036 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
4.73%
|
+25.00% |
| 5 | Aurobindo Pharma
INE406A01037 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
4.37%
|
+23.76% |
| 6 | Ajanta Pharma
INE031B01049 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
3.99%
|
+13.53% |
| 7 | Mankind Pharma
INE634S01028 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
3.89%
|
+8.02% |
| 8 | Lupin
INE326A01037 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
3.73%
|
+7.76% |
| 9 | Abbott
INE358A01014 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
3.65%
|
-10.20% |
| 10 | Fortis Healthcare
INE061F01013 |
Healthcare Medical Care Facilities |
India |
3.31%
|
+11.88% |
About this scheme
The scheme provides long term capital appreciation by investing in equity/equity related instruments of the companies in the Pharmaceuticals, Healthcare and Allied sectors in India. The Scheme does not guarantee/indicate any returns. There can be no assurance that the schemes’ objectives will be achieved.
Fund manager(s): Dhaval Shah
Exit load: Exit load of 1% if redeemed within 30 days.
Scheme snapshot
VR Rating
MS Rating
Plan
Growth
Type
DIRECT
Inception
11 Jul 2019
Lump-sum min
₹1,000
SIP
Purchase
Switch
STP
SWP
Similar schemes
RANKED BY 1Y RETURN
Nippon India Taiwan Equity Fund Direct Growth
1▲ 104.1 pts ahead of this fund
Franklin Asian Equity Fund Direct Growth
2▲ 15.9 pts ahead of this fund
Nippon India Japan Equity Fund - Direct Plan - Growth Plan - Bonus Option
3▲ 13.1 pts ahead of this fund
Nippon India Japan Equity Fund Direct Growth
4▲ 13.1 pts ahead of this fund
Bank of India Small Cap Fund Direct Growth
5▲ 11.8 pts ahead of this fund
TRUSTMF Small Cap Fund Direct Growth
6▲ 11.6 pts ahead of this fund